December 31, 2025 - According to the "White Paper on China's Probiotics Market (2025)" released by Frost & Sullivan, driven by the global big health industry boom, China's probiotics market has entered a scientific, precise and diversified 4.0 new stage, with dual-chamber technology and clinical probiotics emerging as core growth engines. In 2024, the overall scale of China's probiotics market reached 128.3 billion yuan, of which clinical probiotics accounted for 7.5 billion yuan, and is expected to grow to 10 billion yuan by 2028 with a CAGR of 7.5%.
        As a representative of dosage form innovation, dual-chamber probiotics adopt a solid-liquid separation design, storing bacterial powder in the upper chamber and liquid prebiotics in the lower chamber. Instant activation is achieved with one click, effectively solving industry pain points such as inactivation, difficulty in swallowing and colonization of traditional probiotics. Currently, this dosage form has expanded to multiple scenarios including beauty and skin care, weight loss and shaping, eye and hair care. For example, GUTX's dual-chamber fresh probiotics improve colonization efficiency through the three-layer mechanism of "oxygen scavenging - colonization - supplementation", opening a new paradigm for the industry.
        The clinical probiotics market shows a steady growth trend, with hospitals and retail pharmacies accounting for over 90% of sales channels. The competitive pattern of leading brands is distinct: Siliankang covers 6,000 grade hospitals nationwide and is recommended by expert consensus for 16 diseases; Jinshuangqi rapidly supplements probiotics through the synergistic effect of three strains; Bioflor has established advantages with 60 years of global application history and more than 130 clinical studies. From April 2024 to March 2025, Siliankang ranked first in the clinical probiotics market with sales of 1.5308 billion yuan.
        The industry development presents multiple trends: technically, key technologies such as microencapsulation and strain screening continue to make breakthroughs; policy-wise, standards such as the "General Principles for Food Probiotics" promote industrial standardization; market-wise, a three-dimensional matrix of "pharmaceuticals + health products + food" has been formed, with dual-track development of segmented consumer demand and in-depth clinical evidence-based research. With the acceleration of independent strain R&D, the cumulative preservation of China's patented strains has exceeded 31,300, ranking first in the world.

        For more information, you can click: https://www.tiktok.com/@mia_iot